Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FK9H
|
|||
| Drug Name |
Ontuxizumab
|
|||
| Synonyms |
Amatuximab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 2 | [1] | ||
| Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Phase 2 | [2] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [3] | ||
| Company |
EisaiWoodcliff Lake, NJ MorphotekExton, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endosialin (CD248) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.